Astrocytic expression of the chaperone DNAJB6 results in non-cell autonomous protection in Huntington’s disease

Matteo Bason, Melanie Meister-Broekema, Niels Alberts, Pascale Dijkers, Steven Bergink, Ody C.M. Sibon, Harm H. Kampinga

Department of Cell Biology, UMCG and University of Groningen, Ant. Deusinglaan 1, Groningen 9713AV, the Netherlands

ARTICLE INFO

Keywords: Neurodegeneration, Polyglutamine aggregation, Astrocytes, Chaperones, DNAJB6, Prion-like aggregate spreading

ABSTRACT

Several neurodegenerative diseases like Huntington’s, a polyglutamine (PolyQ) disease, are initiated by protein aggregation in neurons. Furthermore, these diseases are also associated with a multitude of responses in non-neuronal cells in the brain, in particular glial cells, like astrocytes. These non-neuronal responses have repeatedly been suggested to play a disease-modulating role, but how these may be exploited to delay the progression of neurodegeneration has remained unclear. Interestingly, one of the molecular changes that astrocytes undergo includes the upregulation of certain Heat Shock Proteins (HSPs) that are classically considered to maintain protein homeostasis, thus resulting in cell autonomous protection. Previously, we discovered DNAJB6, a member of the human DNAJ family, as potent cell autonomous suppressor of PolyQ aggregation and related neurodegeneration. Using cell type specific expression systems in D. melanogaster, we show that exclusive expression of DNAJB6 in astrocytes (that do not express PolyQ protein) can delay neurodegeneration and expands lifespan when the PolyQ protein is exclusively expressed in neurons (that do not co-express DNAJB6 themselves). This provides direct evidence for a non-cell autonomous protective role of astrocytes in PolyQ diseases.

1. Introduction

Heat Shock Proteins (HSPs) are key regulators of the cellular protein quality control (PQC) system (Hartl et al., 2011). In addition to their roles in protein folding, protein transport and protein complex remodelling, HSPs have also been implied in the disaggregation, as well as in the degradation of un- or misfolded proteins (Kakkar et al., 2014). Many age-related neurodegenerative diseases (NDs) are characterized by protein aggregates in neurons and these are thought to initiate or drive their pathology and degeneration (Kakkar et al., 2014; Kampinga and Bergink, 2016). These findings have led to the speculation that an age-related decline in PQC may be key to disease initiation (Balch et al., 2008) and also suggested that boosting the (selective) activity of components of the cellular PQC such as HSPs may hold promises for counteracting NDs (Kakkar et al., 2014; Kampinga and Bergink, 2016; Balch et al., 2008).

In line with these hypotheses, we and others have performed several forward genetic screens to identify specific HSPs within the PQC network that may serve to prevent the aggregation of disease-related proteins and thereby delay the onset of NDs (Hageman et al., 2011; Vos et al., 2010; Hageman et al., 2010; Kakkar et al., 2016a). In such screens, we identified DNAJB6, a human HSP of the DNAJ family and HSP70 co-chaperone, as a very potent and cell autonomous inhibitor of protein aggregation in different in vitro and in vivo models of PolyQ diseases (Hageman et al., 2011; Kakkar et al., 2016b), including Huntington’s disease (HD, OMIM:#143100), which is characterized by the aggregation of mutant PolyQ Huntingtin (HTT). DNAJB6 is a ubiquitously expressed and non-stress-regulated co-chaperone of HSP70 that forms highly dynamic oligomers (Hageman et al., 2011; Kakkar et al., 2016b). It can bind to early intermediates (but not to monomers) of PolyQ containing peptides that initiate fibril formation via direct interaction to the amyloidogenic core (i.e. the polyQ sequence) of polyglutamine containing protein fibrils, thus potently preventing primary nucleation and (to a lesser extent) also secondary nucleation (Kakkar et al., 2016b; Gillis et al., 2013; Månsson et al., 2014). DNAJB6 differs from other HSPs (such as HSP70 and DNAJB1) that cannot suppress aggregation by the core PolyQ peptide, although they can act on sequences flanking the amyloidogenic PolyQ core (Hageman et al., 2011;
Månsson et al., 2014). In line, DNAJB6 has been shown to inhibit aggregation not only of PolyQ HTT, but also of PolyQ ATXN3 and PolyQ androgen receptor (Hageman et al., 2010). This specific function of DNAJB6 is dependent on a unique S/T-rich region in DNAJB6, which is exposed on the DNAJB6 surface and where the amyloid-forming peptides can bind (Kakkar et al., 2016b; Söderberg et al., 2018; Månsson et al., 2018). In addition to protein aggregation, a common hallmark of nearly all aggregation-related NDs is the reactivity of astrocytes, a specific type of glial cells that normally contributes to the brain homeostasis and supports the neuronal functions (Sofroniew and Vinters, 2010). The astrocytic response during aggregation-related NDs is found in degenerating areas of the brain and is characterized by a spectrum of progressive molecular, cellular and functional changes (Sofroniew and Vinters, 2010; Ben Haim et al., 2015), which are most likely a response triggered by the neuronal damage. On one hand, the (early) astrocytic response has repeatedly been suggested to serve in a protective manner to counteract the progression of neurodegeneration. On the other hand, (chronic) astrocytic reactivity has also been suggested to be a maladaptive response that leads to disease aggravation (Sofroniew, 2009).

Interestingly, one of the molecular changes detected in astrocytes in human brains affected by neurodegeneration includes the up-regulation of certain HSPs (Durrenberger et al., 2009; Seidel et al., 2012; Wilhelmus et al., 2006; Dabir et al., 2004), including DNAJB6 (Durrenberger et al., 2009). However, the functional implications of HSPs-up-regulations for the progression of neuronal degeneration have not yet been established.

To fully explore whether and how the expression of HSPs contributes to neuroprotection in NDs, we generated D.melanogaster models that exclusively express PolyQ-HTT in neurons, whilst co-expressing human DNAJB6 either in the same neurons (to study cell autonomous effects) or in astrocytes (to study non-cell autonomous effects).

Our studies show that human DNAJB6 can provide cell autonomous protection against PolyQ mediated neurodegeneration in D. melanogaster (Sofroniew and Vinters, 2010). Interestingly, one of the molecular changes detected in astrocytes in human brains affected by neurodegeneration includes the up-regulation of certain HSPs (Durrenberger et al., 2009; Seidel et al., 2012; Wilhelmus et al., 2006; Dabir et al., 2004), including DNAJB6 (Durrenberger et al., 2009). However, the functional implications of HSPs-up-regulations for the progression of neuronal degeneration have not yet been established.

To fully explore whether and how the expression of HSPs contributes to neuroprotection in NDs, we generated D.melanogaster models that exclusively express PolyQ-HTT in neurons, whilst co-expressing human DNAJB6 either in the same neurons (to study cell autonomous effects) or in astrocytes (to study non-cell autonomous effects).

Our studies show that human DNAJB6 can provide cell autonomous protection against PolyQ mediated neurodegeneration in D. melanogaster, which is associated with a reduction in the PolyQ-HTT aggregate load in fly brains. Strikingly, the exclusive expression of DNAJB6 in astrocytes also provides non-cell autonomous protection against progressive neuronal degeneration and prolongs organismal life span.
Fig. 2. Pan-Neuronal expression of PolyQ-HTT causes aggregate formation and reduces lifespan in D. melanogaster. A) Western Blots of total head lysates of 5 and 15-day-old adult male flies expressing the indicated transgenes in all neurons. Anti-huntingtin antibody for detection of monomers (100 kDa), cleaved products (70 kDa), intermediate aggregated species (130–170 kDa) and HMW aggregates (stacking gel) of HttQ100-mRFP. Tubulin was used as loading control. Number of fly heads per each lysate sample and genotypes in Materials and Methods. B) Lifespan of the same isogenised males flies expressing HttQ100-mRFP or control transgene (eGFP or only promoter) in all neurons. Lifespan of HttQ100-mRFP-expressing line (red curve) is significantly reduced compared to the eGFP-expressing control line (green curve). Detailed statistics, comparisons and genotypes are provided in Fig. S2-1B. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

2. Materials and methods

2.1. Vectors

UAS/LexO vectors were obtained by cloning the sequences of HttQ100-mRFP (Prof. T. Littleton Group, MIT) or V5-DNAJB6 (isoform 2. Materials and methods Ganetzky, 2015). attB pLexO species, a capacity that is enhanced by DNAJB6 expression (Brundin et al., 2010; Costanzo and Zurrulo, 2013; Ren et al., 2009; Babcock and Ganetzky, 2015).

2.2. D. melanogaster stocks

The D. melanogaster lines of Table T1 were obtained by injection and transformation of embryos with the above mentioned attB vectors, based on attP-site specific PhiC31 integrase system, by Best Gene Inc. injection service. D. melanogaster lines from Bloomington Drosophila Stock Center were also used: gmr-Gal4 (Line BDSC #8121 in Fig. 1); gmr-Gal4 (Line BDSC #1104 in Fig. S1-1); alrm-Gal4 (Line BDSC #67031 in Fig. S1-1); mcd8-GFP (Line BDSC #5130); mcd8-RFP (Line BDSC #27391); UAS-ATXN3-Q78 (Line BDSC #8150 in Fig. S1-1); gmr-QF2 (Line BDSC #59283 in Fig. S1-1 was a gift from C. Potter, Baltimore, MD, U.S.A.). gmr-QF2 and QUAS-ATXN3-Q78 are based on the Q expression system in D. melanogaster (Potter et al., 2010).

2.3. Genotypes

Fig. 1: w(−); UAS HttQ100-mRFP / + (or UAS DNAJB6); gmr Gal4 / UAS mCD8-GFP (or +). Fig. S1-1: for cell-autonomous rescue: w(−); gmr-Gal4; UAS ATXN3-Q78/ UAS DNAJB6 (or +); +/+ . For non-cell autonomous rescue: w(−),gmr-QF2; alrm-Gal4; QUAS ATXN3-Q78/ UAS DNAJB6 (or +); +/+ . Fig. 2A, S2-1A: w(−); UAS HttQ100-mRFP (or UAS eGFP) / +; elav Gal4/+ . Fig. 3B and S3-1H: 1) Control line (red): w(−); UAS HttQ100-mRFP / +; elav LhG; elav Gal4 / LexO eGFP. 2) Rescued line (blue): w(−); UAS HttQ100-mRFP / elav LhG; elav Gal4 / LexO DNAJB6. Fig. S3-1B: 1) active combinations w(−); UAS eGFP (D) / +; promoter Gal4/A or w(−); promoter Gal4/A; +/+ or w(−); promoter Gal4/A; LexO eGFP (A) /+. Fig. S3-1C: w(−); UAS eGFP/+; promoter Gal4/A or w(−); promoter LexA (LG or LhG)/+; Lexo eGFP/+; Negative control: w(−); +/+ or w(−); promoter Gal4/A; Lexo eGFP (A) /+. Fig. S3-1D: w(−); UAS eGFP (D)/+; promoter Gal4/A or w(−); promoter LexA (LG or LhG)/+; Lexo eGFP (A)/+. Negative control: w(−); +/+ or w(−); promoter Gal4/A; Lexo eGFP (A) /+. Fig. 4A and B: w(−); UAS mCD8-RFP(or UAS HttQ100-mRFP) / alrm LhG; gal4 / Lexo eGFP. 2) Rescued line (blue): w(−); UAS HttQ100-mRFP / promoter(reo or alrm) LhG; gal4 / Lexo eGFP. 3) Control line (Fig. 5B, panel 2 and Fig. S5-1E, panels 4–6): w(−); UAS HttQ100-mRFP / alrm LhG; gal4 / Lexo eGFP. 4) Control line (Fig. 5B, panel 2 and Fig. S5-1E, panels 4–6): w(−); UAS HttQ100-mRFP / alrm LhG; gal4 / Lexo eGFP. 5) Condition (Fig. 5B, panel 2 and Fig. S5-1E, panels 7–9; Fig. 5C and Supplementary Movie M1): w(−); UAS HttQ100-mRFP / alrm LhG; gal4 / Lexo DNAJB6. 6) Control (Fig. 5B, panel 2 and Fig. S5-1E, panels 4–6): w(−); UAS HttQ100-mRFP / alrm LhG; gal4 / Lexo eGFP. 2) Rescued line (blue): w(−); UAS HttQ100-mRFP / promoter (reo or alrm) LhG; gal4 / Lexo DNAJB6. 3) Control (Fig. 5B, panel 2 and Fig. S5-1E, panels 7–9; Fig. 5C and Supplementary Movie M1): w(−); UAS HttQ100-mRFP / alrm LhG; gal4 / Lexo DNAJB6.

2.4. Antibodies and reagents

Antibodies (dilutions are indicated in brackets for western blots (WB) and immunofluorescence (IF)) against huntingtin (Chemicon, MAB2166, WB 1:5000), eGFP (Clontech-Living Colours, cat.No.632375, WB 1:5000), α-tubulin (Sigma Aldrich, clone DM1A, WB 1:2000), V5 epitope tag in DNAJB6 (Thermo Fisher Scientific, cat. No.R960-25, WB 1:2000, IF 1:50), NC-82 (DSHB, WB 1:5000) were used. DAPI for nuclei staining (cat.No.D1306) was from Thermo Fisher Scientific. 20%
2.5. D. melanogaster stocks maintenance

All stocks and experimental flies were kept in polystyrene vials 25 × 95 mm filled with 8 ml/vial of solidified media (17 g/l Agar; 26 g/l Yeast; 54 g/l Sugar; 1.3 mg/l Nipagin). All experimental flies were maintained in a humidified and temperature controlled incubator at 25 °C on a 12 h’ light and 12 h’ dark cycle (Premium ICH Insect Yeast; 54 g/l Sugar; 1.3 mg/l Nipagin). All experimental flies were kept in polystyrene vials (5–6 females and 5–6 males) were kept in vial for 3 days and then removed. Oocytes from females were collected and kept in new vials (10 females per vial). Flies anesthetized on a CO2 pad and their GFP fluorescent eyes in D.melanogaster was quantified.

2.6. Lifespan curves

Parental flies (5–6 females and 5–6 males) were kept in vial for 3 days and then removed. Offspring virgin flies were collected in the same 24 h. For each analysed group, ≈ 100 flies of specific gender and phenotype were collected and kept in new vials (10 flies/vial). Flies were transferred to new vials containing fresh medium every 2 days and deaths were scored daily. Statistical significance of curves differences analysed with Log rank (Mantel-Cox) test (test 1) and Gehan-Breslow-Wilcoxon test (test 2) using Graph Pad Prism Software Version 5.00. All curves comparisons were made from flies analysed in the same experiment. T50 was defined as the time point at which 50% of the initial population has died.

Fig. 3. Effect of neuronal DNAJB6 expression on PolyQ-HTT aggregate formation and lifespan in a pan-neuronal HttQ100-mRFP D. melanogaster model. A) Lifespan of isogenised male flies co-expressing neuronal (N > ) HttQ100-mRFP and neuronal (N > ) DNAJB6 or eGFP. Lifespan of DNAJB6-expressing line (blue curve) is significantly expanded compared to the control line (red curve). Additional control lines, comparisons and genotypes are provided in Fig. S3-1 E, G. B) Western Blots of total head lysates of 5 and 15-day-old adult female flies (with equal transgenes expression of flies in Fig. 3A). Anti-huntingtin antibody used for detection of monomers (100 kDa), cleaved products (70 kDa), intermediate aggregated species (130–170 kDa) and HMW aggregates (stacking gel) of HttQ100-mRFP. Anti-V5 antibody for (V5 tagged) DNAJB6 detection. Anti-GFP antibody for eGFP detection. Tubulin was used as loading control. HMW aggregates of HttQ100-mRFP quantification (signal in stacking gel normalized on tubulin signal; a.u.: arbitrary units) for each line is shown. Number of fly heads per each lysate sample and genotypes in Materials and Methods. An independent repeat of the experiment is shown in Fig. S3-1H. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

2.7. Western Blotting D. melanogaster total head lysates preparation

30–40 D. melanogaster adults with specific phenotype, gender, age (days after pupal eclosion) and condition were collected; after freezing in liquid nitrogen and vortexing of entire flies, separated heads were collected, counted and lysed in SDS-rich buffer (SDS 1.45%, Glycerol 20%; Tris Base 0.2 M. 2.5 μl of buffer/head) using sonication (3 pulses of 50 W for 5 s). Homogenized lysate was then centrifuged at 1000 x g for 3 s to separate cuticle debris from supernatant. Proteins in supernatant were collected and quantified using spectrophotometer (Implant NanoPhotometer UV/Vis). Protein content was equalized. Samples, supplied with β-mercaptoethanol 5% and bromophenol blue, were boiled at 99 °C for 5 min. Equal amounts of volume were resolved on SDS-PAGE. Flies of the same line were collected from different vials and the entire experiment was repeated at least 2 times.

2.8. Western Blotting and Blot quantification

Following the preparation of samples, proteins were resolved by SDS-PAGE, transferred to nitrocellulose membrane and processed for Western Blotting. Primary antibodies (at concentrations mentioned above) were prepared in 3% BSA/PBS-Tween 20 0.1%, secondary antibodies at concentration 1:5000 (Invitrogen, horse peroxidase conjugated to IGG or IGM) in 5% milk/PBS-Tween 5.0.0. For visualization membranes were incubated with Pierce ECL Western Blotting substrate (cat. No. 32106) for 2 min and visualized using ChemiDoc Touch Imaging System (BioRad). Blots have been quantified using Image Lab Version 5.2.1 software (BioRad).

2.9. Imaging of fluorescent eyes in D.melanogaster and quantification

Experimental D. melanogaster adults with specific phenotype, gender, age (days after pupal eclosion) and condition were kept anesthetized on a CO2 pad and their GFP fluorescent eyes were visualized
using Leica MZ10 F Fluorescence stereomicroscope (GFP3 filter). 10 eyes of different flies / group were visualized and GFP fluorescence was quantified using Image J 1.48v software and expressed as corrected mean eye fluorescence (CMEF). CMEF has been calculated as: Integrated Density - (Selected Area x Mean Background Fluorescence). Statistical significance of CMEF differences analysed with 1-way ANOVA test using Graph Pad Prism Software Version 5.00.

2.10. Analysis of eye degeneration at light microscope

For each condition, at least 80 fly eyes were checked. The fraction of the eyes that showed degeneration phenotype were calculated as previously (Vos et al., 2010). For each analysed line, eyes of at least 40 flies were scored. The results were average of at least three independent experiments.

2.11. D. melanogaster Immunofluorescence (IF), Imaging and Punctae Quantification

Brains of experimental D. melanogaster adults with specific phenotype, gender, age (days after pupal eclosion) and condition were dissected by light microscope visualization, in 0.1% Triton X-100 PBS 1× buffer and then fixed in 3.7% Formaldehyde, 0.1% Triton X-100 PBS 1× buffer for 20 min at room temperature. Staining of brains was
**A**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Days 5</th>
<th>Days 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neur.&gt;HttQ100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Glia&gt;eGFP</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Glia&gt;DNAJB6</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Atr:&gt;eGFP</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Atr:&gt;DNAJB6</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**B**

**Neuronal mCD8-RFP + Astrocytic eGFP:**

**C**

**Neuronal HttQ100-mRFP + Astrocytic DNAJB6:**

**D**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Days 5</th>
<th>Days 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neur.&gt;mCD8-RFP</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Neur.&gt;HttQ100-mRFP</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Atr:&gt;eGFP</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Atr:&gt;DNAJB6</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**E**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Days 5</th>
<th>Days 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neur.&gt;HttQ100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neur.&gt;&gt;eGFP</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Neur.&gt;&gt;DNAJB6</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Atr:&gt;eGFP</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Atr:&gt;DNAJB6</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**F**

**NC82, 15 days:**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>NC82</th>
<th>Tubulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neur.&gt;HttQ100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neur.&gt;&gt;eGFP</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Neur.&gt;&gt;DNAJB6</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**NC82, 15 days:**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>NC82</th>
<th>Tubulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neur.&gt;HttQ100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neur.&gt;&gt;eGFP</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Neur.&gt;&gt;DNAJB6</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>
performed by blocking not specific sites using 2% BSA, 0.1% Triton X-100 PBS 1× buffer for 30 min at room temperature, then incubating with primary antibody (dilution 1:50) in blocking buffer for 2 days at 4 °C and finally with secondary Alexa-conjugated dyes antibody (Invitrogen, Alexa Fluor 488 goat-anti-mouse; dilution 1:500) and DAPI (final concentration 0.2 μg/μl) in blocking buffer for 2 days at 4 °C, to respectively visualize primary antibodies and nuclei. Brains were mounted between glass slide and coverslip, embedded in mountant solution (CitiFluor, Agar Scientific) and visualized by confocal microscopy within 24 h. If images of D.melanogaster brains were captured using confocal laser scanning microscope (Leica TCS SP8). Z-stack images were obtained to check for the punctae in cells at different Z-planes. Quantification of the punctae in cells was carried out manually. Photoshop, and Image J software were used for image processing and to generate the 3D reconstruction (Supplementary Movie M1). Statistical significance of values differences analysed with 1-way ANOVA test using Graph Pad Prism Software Version 5.00.

3. Results

In order to test whether and how the expression of HSPs in astrocytes might be relevant for neuroprotection in PolyQ diseases, we decided to use DNAJB6, one of the most potent human chaperones in providing protection against these diseases in different in vitro and in vivo models (Hageman et al., 2010; Kakkar et al., 2016b).

We first verified whether this protective function of human DNAJB6 against PolyQ aggregation was also maintained in D. melanogaster. To do so, we first used the omatidial integrity of transgenic D. melanogaster lines as readout for PolyQ-mediated degeneration. Hereto, the construct HttQ100-mRFP (encoding for human PolyQ-HTT exons 1–12; Weiss et al., 2012) was expressed in fly omatidia together with human DNAJB6 (short nuclear and cytosolic isoform B; Hanai and Mashima, 2003) and the membrane-targeted mCD8-GFP (a quantifiable fluorescent reporter of internal ommatidia integrity, established and validated in different D.melanogaster omatidial-models of PolyQ diseases; Burr et al., 2014), using the gmr promoter driven by the Gal4-UAS expression system (Brand and Perrimon, 1993). The sole expression of HttQ100-mRFP caused a significant reduction in mCD8-GFP fluorescence in omatidia (Fig. 1A, B) and in total mCD8-GFP protein levels (Fig. 1C, D), indicating the degeneration of omatidia. Both endpoints were alleviated by co-expression of DNAJB6 in the same cells (Fig. 1A-D), which implies a cell-autonomous protective effect of this HSP against HttQ100-mRFP toxicity. Notably, HttQ100-mRFP aggregation and mCD8-GFP levels are inversely correlated, further validating the use of this reporter, and confirming previous mechanistic findings that DNAJB6 can directly prevent the aggregation of PolyQ proteins in a cell-autonomous manner (Hageman et al., 2010; Kakkar et al., 2016b). Comparable data were found when co-expressing DNAJB6 with a truncated ataxin-3 (ATXN3) carrying an expanded PolyQ (ATXN3-Q78) (Warrick et al., 1998), responsible for spinocerebellar ataxia type 3 (OMIM:#109150) (Costa and Paulson, 2012) (Fig. S1-1A). This confirms our previous findings that the protective action of DNAJB6 is generic for the core PolyQ-expansion (Månsson et al., 2014) and independent from regions flanking the PolyQ expansion for which it is known that they can affect the aggregation propensity of the PolyQ-containing protein (Kuiper et al., 2017). In line with the protective action against cell degeneration, DNAJB6 expression also resulted in a reduction in the amount of HttQ100-mRFP aggregates in total head lysates (Fig. 1C, D).

Next, we generated a D. melanogaster line expressing HttQ100-mRFP in all neurons using the validated and well-characterized pan-neuronal promoter elav-Gal4 (Yao et al., 1993). Western blots of total head lysates showed abundant levels of HTT monomers, cleaved products, aggregating intermediates and high molecular weight (HMW) HTT-aggregates in 5-day-old adult male (Fig. 2A) and female (Fig. S2-1A) flies. In 15-day-old adults, monomers and other intermediate species were remarkably decreased and HMW aggregates were still present, indicating progressive aggregation and a worsening of the HD-phenotype. Lifespan analysis showed a significant reduction in lifespan of HttQ100-mRFP expressing males (Fig. 2B), with a T50 decrease of 55% (Fig. S2-1B; a comparable effect has been also observed in females, data not shown).

Subsequently, we used the GAL4-UAS and LexA-LexO (Yagi et al., 2010) expression systems that can drive expression of transgenes in a completely independent and non-overlapping manner (Fig. S3-1A-D). We generated lines co-expressing HttQ100-mRFP regulated by GAL4-UAS and DNAJB6 by LexA-LexO, solely in neurons (using the elav promoter). Neuronal expression of DNAJB6 extended the lifespan of flies co-expressing neuronal HttQ100-mRFP, increasing the T50 by 43% (Fig. 3A, Fig. S3-1G). The line co-expressing neuronal eGFP and HttQ100-mRFP showed a lifespan comparable to that of flies expressing neuronal HttQ100-mRFP only (compare Fig. 2B, Fig. S2-1B with Fig. 3A, Fig. S3-1E, G). This indicates that combined use of multiple promoters and eGFP expression was without any biological consequences, meaning that the lifespan reduction in the line co-expressing neuronal eGFP and HttQ100-mRFP of Fig. 3A is primarily due to the expression of the toxic PolyQ protein. Expression of DNAJB6 in neurons of control flies did not result in lifespan modulating effects (Fig. S3-1F, G), indicating that the protection in the PolyQ model is not due to a non-specific fitness-enhancing effect of DNAJB6. Again, in line with the previous observations (Hageman et al., 2010; Kakkar et al., 2016b) and the data on D.melanogaster eyes-degeneration (Fig. 1), we found that...
neuronal expression of DNAJB6 also reduced the amount of HttQ100-mRFP aggregates in total head lysates (Fig. 3B, Fig. S3-1H). Together these data imply and confirm that DNAJB6 has a specific and cell-autonomous protective activity against HttQ100-mRFP mediated toxicity in neurons that is associated with its ability to reduce PolyQ aggregate formation (Månsson et al., 2014). Notably, brain cell degeneration due to HttQ100-mRFP toxicity might lead to reduction expression of the various transgenes during the time and disease progression, but this does not change the overall conclusion of the above described experiments.

Astrocytes have been suggested to play a key role in many aggregate-related NDs, including HD (Sofroniew and Vinters, 2010; Ben Haim et al., 2015). On the one hand, it has been suggested that the neuronal damage leads to astrocyte reactivity, which compromises their functions in nourishing and protecting neurons. On the other hand, data from rodent HD models and indirect evidence derived from human HD brains (Jansen et al., 2016) suggested that PolyQ-HTT may also be directly toxic to astrocytes, thus contributing to their chronic reactivity and to a neurodegenerative phenotype. In line with these findings and those from rodent models expressing PolyQ-HTT in astrocytes (Shin et al., 2005; Bradford et al., 2009), we observed that the selective expression of HttQ100-mRFP in the astrocytes of D. melanogaster (using the validated and characterized astrocyte-specific arn-Gal4 promoter; Doherty et al., 2009) reduced the lifespan of the cohort (Fig. S4-1A, F).

Astrocytes are generally considered to be more resistant to PolyQ-HTT aggregation and toxicity than neurons (Jansen et al., 2014; Jansen et al., 2016) and hence PolyQ diseases are primarily thought to be due to neuronal dysfunction and death. Moreover, although chronic astrocyte reactivity is considered to be detrimental, the initial astrocytic responses have been suggested to actually counteract the progression of neurodegeneration. However, direct evidence to substantiate this hypothesis is lacking. Importantly, altered expression of several HSps in astrocytes are amongst such molecular changes (Durrenberger et al., 2009; Seidel et al., 2012; Wilhelmus et al., 2006; Dabir et al., 2004), the relevance of which has not been demonstrated so far.

Having established that the neuronal cell-autonomous protection of human DNAJB6 is recapitulated in the D. melanogaster system, we addressed whether the up-regulation of chaperones, like DNAJB6, in astrocytes might non-cell autonomously protect neurons against PolyQ mediated degeneration. To test this hypothesis, we selectively expressed DNAJB6 in astrocytes (using the specific promoter arn-LexA; Doherty et al., 2009), or in all glial cells (using the pan-glial promoter repo-LexA; Xiong et al., 1994), in the flies co-expressing HttQ100-mRFP in neurons (Fig. S3-1A-D and Fig. 4). Whereas PolyQ-HTT is ubiquitously expressed in HD human brains and rodent models of HD like R6/2 mice, in our fly model the PolyQ protein, HttQ100-mRFP, is exclusively expressed in neurons, but not in astrocytes or glial cells (Fig. 4); this enabled us to exclusively investigate whether astrocytic/glial DNAJB6 expression might exert non-cell autonomous protective effects against the toxicity mediated by the PolyQ proteins expressed in neurons. The tissue-specific expression via each of these promoters was confirmed by confocal microscopic analysis: control brains with mCD8-RFP and eGFP in astrocytes show non-overlapping staining as evidenced by diffuse mCD8-RFP fluorescent in neuronal lobes (e.g. antennal lobes, mushroom bodies), surrounded by a network of eGFP-positive astrocytes with ramified processes (Fig. 4A). Staining of brains of flies expressing neuronal HttQ100-mRFP was slightly lower. HttQ100-mRFP foci reminiscent of aggregate formation, were mainly detected in the neurons (Fig. 4B).

Strikingly, the exclusive expression of DNAJB6 in all glial cell types significantly expanded the lifespan of flies expressing pan-neuronal HttQ100-mRFP, increasing the T50 by 23% (Fig. 4C, Fig. S4-1B, F). In fact, the exclusive expression of DNAJB6 in astrocytes only resulted in a similar lifespan extension in flies expressing pan-neuronal HttQ100-mRFP (25%, Fig. 4D, Fig. S4-1C, F), indicating that the expression of DNAJB6 in this specific type of glial cells alone suffices to provide non-cell autonomous protection against PolyQ mediated toxicity. The lifespan extension in these lines is also not as pronounced as observed when DNAJB6 is expressed in neurons (in which T50 is increased by 43%; Fig. 3A, Fig. S3-1G), suggesting that the pro-survival mechanisms mediated by DNAJB6 expression differ in different cell types might be mechanistically distinct and not completely equal in terms of effectiveness. Similar to what we found for exclusive DNAJB6 expression in neurons, DNAJB6 expression in all glial cells (Fig. S4-1D, F) or astrocytes (Fig. S4-1E, F) did not affect lifespan in control flies, indicating its specific effect on HttQ100-mRFP related toxicity. In a similar approach, we also found that DNAJB6 expression in astrocytes alleviated the level of eye degeneration caused by expression of ATXN3-Q78 in fly ommatidia (Fig. S1-1B).

In order to investigate the mechanism underlying this non-cell autonomous protection, we first considered the possibility of intercellular transmission of DNAJB6 from glial cells to neurons (Takeuchi et al., 2015) (Fig. S5-1A). For this hypothesis to be true, such a transfer should lead to reduced aggregation of HttQ100-mRFP, similar to what we observed for the cell-autonomous protection via the expression of DNAJB6 in neurons (Fig. 3B, Fig. S3-1H). However, DNAJB6 expression in all glial cells or astrocytes was not associated with a comparable dramatic reduction of HMW HttQ100-mRFP aggregates in total head lysates (Fig. 5A, Fig. S5-1B). These data confirm the specificity of the used expression systems. More importantly, these data imply that the intercellular glia-to-neurons transmission of DNAJB6 is unlikely the only or the dominant mechanism for the non-cell autonomous protective effects of DNAJB6 on the lifespan of neuronal HttQ100-mRFP flies.

In view of these results, we next investigated if other additional pro-survival and non-cell autonomous mechanisms would take place when DNAJB6 is expressed in astrocytes. It has been suggested that PolyQ-HTT aggregates may spread throughout the brain in a prion-like manner (Brundin et al., 2010; Costanzo and Zurzolo, 2013; Ren et al., 2009; Babcock and Ganetzky, 2015) (Fig. S5-1C) and that this progressive spread of disease-associated proteins contributes to the progression of the neurodegenerative process. In theory, astrocytes might restrict such spreading via actively taking up prion-like protein species, a capacity that might be limited by the progressive accumulation of toxic aggregates (Pearce et al., 2015) (Fig. S5-1C). In line with this idea, confocal microscopic analysis of flies co-expressing neuronal HttQ100-mRFP and astrocytic eGFP, revealed that approximately ~10% of eGFP-expressing astrocytes, contained mRFP punctae (Fig. 5B, D; Fig. S5-1D, S5-1E). These puncta are reminiscent of protein aggregation and under all conditions are qualitatively associated with the relative amounts of insoluble proteinaceous material detected in our western analyses. This phenomenon was not due to indiscriminate protein transfer, as shown by the absence of mRFP punctae in eGFP astrocytes of the control line expressing neuronal non-aggregating membrane-bound mCD8-RFP (Fig. 5B, D; Fig. 5D, E). These data support the hypothesis that PolyQ HTT aggregates can indeed be transferred from neurons to astrocytes. Importantly, the combined expression of neuronal HttQ100-mRFP with astrocytic DNAJB6 resulted in a significant increase in the frequency of astrocytes with mRFP punctae to ~50% (Fig. 5B-D; Fig. S5-1D, S5-1E), suggesting that DNAJB6 expression positively influenced the capacity of astrocytes of taking up such prion-like species (Fig. S5-1C). 3-D confocal analyses confirmed that HttQ100-mRFP aggregates are indeed inside astrocytes (Fig. 5C, Supplementary Movie M1); To confirm that the expression of astrocytic DNAJB6 indeed resulted in the actual and specific non-cell autonomous protection of neurons, we analysed the level of the neuronal marker NC82 (Wagh et al., 2006) in total fly head lysates. NC82 (Bruchpilot) is a key synaptic protein for the activity and integrity of the pre-synaptic zone in D.melanogaster brain (Wagh et al., 2006). NC82 is critical for a normal-evoked neurotransmitter release at the chemical synapses and, notably, the RNAi-induced-reduction of neuronal NC82 expression leads to an alteration of the normal synaptic components, to locomotor inactivity, and to unstable flight in adult D. melanogaster (Wagh et al., 2006). The expression level of NC82 provides therefore a direct measure of the functional fitness of the neuronal.
population. We found NC82 levels to be strongly decreased in 15-day-old flies solely expressing neuronal HttQ100-mRFP (Fig. S5-1F, G). This NC82-decline was not only alleviated in flies co-expressing neuronal DNAJB6 (cell autonomous protection), but also in flies co-expressing DNAJB6 in astrocytes (non-cell autonomous protection, Fig. 5E, F, Fig. S5-1H, I), implying an overall improvement of overall neuronal fitness in both cases.

4. Discussion

Our data are a direct demonstration of a long-assumed hypothesis that glial cells, and particular astrocytes, might play a modulating role in HD, which as in many other NDs, initially and primarily affects neurons.

PolyQ-HTT is expressed in glial cells in the brain of HD patients and animal models (Jansen et al., 2016). In line with previous data from rodent models (Shin et al., 2005; Bradford et al., 2009), we confirmed that PolyQ-Htt exclusively expressed in astrocytes reduces lifespan in D. melanogaster. These data thus indicate that astrocytic PolyQ-HTT may contribute to HD pathology and that astrocytic damage is generally detrimental to the health of the brain, as notably observed in Alexander disease (OMIM: #203450), a genetic neurodegenerative disorder that primarily affects astrocytes by a dominant gain-of-function mutation of the GFAP gene (Sofroniew and Vinters, 2010; Olabarria and Goldman, 2017).

However, our data revealing neuroprotection by expression of DNAJB6 in astrocytes differ from these latter studies (Jansen et al., 2016; Shin et al., 2005; Bradford et al., 2009), as astrocytes in our D. melanogaster model do not express PolyQ-HTT. Still, we found that DNAJB6-expressing astrocytes provide a non-cell autonomous protective effect against degeneration of neurons expressing PolyQ-HTT. Thus, these data for the first time reveal that astrocytes empowered with sufficient chaperone activity, provided by DNAJB6, can provide protection against degeneration of neurons in HD.

DNAJB6, the chaperone used in this study, has cell-autonomous protective effects as previously shown (Kakkar et al., 2016b), which are strongly associated with its ability to prevent the initiation of PolyQ aggregation by the core-polyQ fragment, irrespective of regions flanking the expansion (Hageman et al., 2010; Månsson et al., 2014), for which it is known that they can affect the aggregation propensity of the PolyQ-containing protein (Kuiper et al., 2017). Our findings for both in vivo PolyQ HTT and PolyQ ATXN3 fly models show that also not only the cell autonomous, but also the non-cell autonomous effects of DNAJB6 are generic for PolyQ proteins.

Interestingly, the non-cell autonomous protection evoked by DNAJB6 expression in astrocytes is not associated with a reduction in PolyQ-HTT aggregation. Although it has been suggested that DNAJs and other HSPs can be transmitted between cells via exosomes (Takeuchi et al., 2015), the absence of an effect on total aggregate formation in our study implies that additional mechanisms may underlie the DNAJB6-mediated non-cell autonomous protection.

Despite the use of well-established promoters and two independent expression systems, it could still be argued that low levels of neuronal DNAJB6, due to an eventual leakage of the repo-LexA and alm-LexA promoters and beyond detection limit of our microscopic analyses, could have been responsible for the observed protection evoked by DNAJB6 expression in astrocytes. However, using a weaker elav promoter to drive neuronal DNAJB6 expression than those used in the presented data (i.e. using the elav-LG instead of the elav-LhG promoter (Fig. S3-1A-D and Yagi et al., 2010)) we found no significant cell autonomous protection, whereas we could still detect neuronal DNAJB6 expression (data not shown). This implies that it is highly unlikely that the observed protection by astrocytic DNAJB6 expression is due to leakage of the repo-LexA and alm-LexA promoters.

This implies that the observed non-cell autonomous protection via astrocytic DNAJB6 expression is directly due to an activity of the chaperone in the astrocytes enhancing its fitness and function. We hypothesize such may delay the trans-cellular spreading of PolyQ HTT aggregates in the D. melanogaster brain. Cellular experiments have indeed demonstrated that PolyQ-HTT aggregates can enter cells where they can initiate intracellular seeding (Kakkar et al., 2016b; Ren et al., 2009) and can spread between neurons in the D. melanogaster brain (Babcock and Ganetzky, 2015). Our data show that, in the same organelle system, these neuronal PolyQ-HTT aggregates can end up in astrocytes in agreement with observations by Pearce and colleagues (Pearce et al., 2015), using axotomised neurons. The uptake of neuronal-derived aggregates could imply that astrocytes act as a "reservoir" for these toxic prion-like species, thereby preventing their neuron-to-neuron spreading in the brain and hence delaying the progression of neurodegeneration. The prion-reservoir capacity of astrocytes is likely limited by the toxicity of captured aggregates. However, the upregulation of chaperones like DNAJB6 may enhance this capacity, which is supported by our data showing that the frequency of astrocytes with inclusions is increased in case of DNAJB6 overexpression. This provokes the speculation that DNAJB6 can positively influence the prion-reservoir capacity of astrocytes and their ability to prevent the spreading of prion-like species in the brain, via its protective functions against PolyQ-HTT toxicity (Hageman et al., 2010). The increased prion-reservoir capacity of astrocytes ultimately results in an improvement of overall neuronal fitness and in an increased lifespan of PolyQ-HTT D. melanogaster model (Fig. S5-1C).

An alteration in neuroinflammation could be an additional contributor to the enhanced neuroprotection due to the DNAJB6 expression in astrocytes, which hereby might promote a more neuroprotective or less neurotoxic pathway. Indeed, astrocytic activation has been claimed to have both positive and negative effects on the progression of PolyQ diseases (Sofroniew and Vinters, 2010).

In conclusion, our findings support the hypothesis that increasing astrocyte fitness and functions by chaperones like DNAJB6 (tentatively by increasing their prion-reservoir capacity) has protective significance in HD and possibly other protein aggregation-related NDs which show a pathology associated with these prion-like species such as Alzheimer's (OMIM: #104300) and Parkinson's (OMIM: #168601) (Brundin et al., 2010; Costanzo and Zurzolo, 2013).

Supplementary data to this article can be found online at https://doi.org/10.1016/j.nbd.2018.10.017.

Conflicts of interests

The authors declare no conflict of interest.

Funding

This work was supported by the Princes Beatrice Foundation / de Nederlandse Herenstichting (grant # F2012(1)-104).

Acknowledgments

The authors wish to thank Jeanette F. Brunsting, Wondwossen Melaku Yeshaw, Yixian Li, Serena Carra and Jean-Christophe Billeter for their helpful suggestions.

References

Brand, A.H., Perrimon, N., 1993. Targeted gene expression as a means of altering cell...


